Mesoblast Profit Margin 2012-2021 | MESO
Current and historical gross margin, operating margin and net profit margin for Mesoblast (MESO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Mesoblast net profit margin as of June 30, 2021 is -1325.26%.
|Mesoblast Annual Profit Margins
|Mesoblast Quarterly Profit Margins
||Medical - Biomedical and Genetics
Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.